A novel heterocyclic compound inhibits human breast tumor cells via ROS mediated apoptosis.

The new heterocyclic compound 2-((6-chloro-2-methylpyrimidin-4-yl)amino)-N-(2-chloro-6-methylphenyl) thiazole-5-carboxamide (1), designed using 2-chloro-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide (2) as start material, was successfully obtained via multistep synthesis route and finally characterized by IR (infrared radiation), 1H NMR (nuclear magnetic resonance), and single crystal X-ray crystallography. The inhibitory effect of compound 1 on human breast tumor cell line BS524 was further explored. The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and IC50 (half maximal inhibitory concentration) values suggested that compound 1 has significant anti-proliferation activity on BS524 cells and with low side effect. Then, serial experiments, such as the Annexin V-FITC/PI assay, TUNEL staining and autophagy detection revealed that compound 1 could inhibit cell proliferation via induce cells apoptosis, and the apoptosis is induced by (reactive oxygen species) ROS generation in BS524 cells. [ABSTRACT FROM AUTHOR]